Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Standard ADT Clear all
Active, not recruiting Early Phase 1 Interventional

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

NCT05477823
View directory record Official record
Conditions
Prostate Cancer
Interventions
External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Radiation · Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

NCT02446405
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

NCT04402151
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Not yet recruiting Phase 1 Interventional

IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07803653
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Biopsy Procedure
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

NCT07325721
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Interventions
Hypofractionated radiation with a microboost
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

NCT06846320
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
49
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

NCT02649855
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasms, Neoplasms, Prostatic
Interventions
PROSTVAC-V, PROSTVAC-F, Docetaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Withdrawn Phase 2 Interventional

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

NCT02065323
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard ADT, Dovitinib
Drug
Lead sponsor
Oscar Goodman, Jr.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Radiation · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

NCT04267887
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Prednisone, Computed Tomography, Bone Scan, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Not applicable Interventional Results available

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

NCT05628363
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
Device · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Terminated Phase 2 Interventional Results available

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

NCT03649841
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Abiraterone Acetate, Prednisone, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 13, 2026, 2:37 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

NCT04331717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Obesity, Morbid
Interventions
Bead Block 300-500 um, Weight Management, Lupron
Device · Behavioral · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 2 Interventional

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

NCT04633252
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms
Interventions
PDS01ADC, Docetaxel, M7824, Prednisone, ADT
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Not applicable Interventional

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NCT02735252
View directory record Official record
Conditions
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions
Systemic therapy, StrataNGS
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Not applicable Interventional Results available

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study

NCT04870515
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Best Practice, Dietary Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

NCT04465500
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
Radiation · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 13, 2026, 2:37 AM EDT
Not yet recruiting Phase 2 Interventional

Folate Study in Men With Advanced Prostate Cancer

NCT06536374
View directory record Official record
Conditions
Prostate Cancer
Interventions
Trimethoprim Tablets
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Phase 2 Interventional Results available

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 13, 2026, 2:37 AM EDT
Completed Not applicable Interventional

Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies

NCT06229236
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Navigator
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 13, 2026, 2:37 AM EDT